<p>在今天发布的一份报告中，摩根士丹利的 Judah Frommer 维持了对 RegenXBio 的买入评级，目标价为 16.00 美元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>根据 TipRanks 的数据，Frommer 是一位 2 星分析师，平均回报率为 0.7%，成功率为 52.86%。Frommer 覆盖医疗保健领域，专注于 Evommune, Inc.、Lakefront Biotherapeutics 和 COMPASS Pathways 等股票。</p>
<p>除了摩根士丹利，RegenXBio 还在今天的报告中获得了 Stifel Nicolaus 的 Annabel Samimy 的买入评级。然而，昨天，高盛对 RegenXBio（NASDAQ: RGNX）维持了持有评级。</p>

RGNX

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做多 - Direxion

<p>摩根士丹利分析师 Judah Frommer 重申了对 RegenXBio（RGNX）的买入评级，目标价为 16.00 美元。Frommer 是一位 2 星级分析师，成功率为 52.86%。Stifel Nicolaus 也对 RegenXBio 发布了买入评级，而高盛则维持了持有评级</p>

<p>In a report released today, Judah Frommer from Morgan Stanley maintained a Buy rating on RegenXBio, with a price target of $16.00.</p>
<div class="lb-trans"><p>在今天发布的一份报告中，摩根士丹利的 Judah Frommer 维持了对 RegenXBio 的买入评级，目标价为 16.00 美元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>According to TipRanks, Frommer is a 2-star analyst with an average return of 0.7% and a 52.86% success rate. Frommer covers the Healthcare sector, focusing on stocks such as Evommune, Inc., Lakefront Biotherapeutics, and COMPASS Pathways.</p>
<div class="lb-trans"><p>根据 TipRanks 的数据，Frommer 是一位 2 星分析师，平均回报率为 0.7%，成功率为 52.86%。Frommer 覆盖医疗保健领域，专注于 Evommune, Inc.、Lakefront Biotherapeutics 和 COMPASS Pathways 等股票。</p>
</div><p>In addition to Morgan Stanley, RegenXBio also received a Buy from Stifel Nicolaus’s Annabel Samimy in a report issued today. However, yesterday, Goldman Sachs maintained a Hold rating on RegenXBio (NASDAQ: RGNX).</p>
<div class="lb-trans"><p>除了摩根士丹利，RegenXBio 还在今天的报告中获得了 Stifel Nicolaus 的 Annabel Samimy 的买入评级。然而，昨天，高盛对 RegenXBio（NASDAQ: RGNX）维持了持有评级。</p>
</div>

Morgan Stanley Sticks to Its Buy Rating for RegenXBio (RGNX)

Tip Ranks

Regenxbio

摩根士丹利

Evommune

Lakefront Biotherapeutics

Compass Pathways

Stifel Financial

高盛

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

GS Hldg R

摩根士丹利维持对 RegenXBio (RGNX) 的买入评级